CRISPR

The early phase, first-in-human trial aims to correct the sickle mutation in blood stem cells that causes the disease

The test uses CRISPR-Cas technology to target and detect the novel coronavirus 

CRISPR-based diagnostics can offer quick and accurate nucleic acid testing for infectious and noninfectious diseases

CRISPR-Cas systems can improve the speed, sensitivity, and specificity of diagnostic tests, but are they ready for prime time?

With the new gene editing technique, researchers can program sequential genome edits over time

Base editors hold great promise for safer multiplex gene editing

From discovery and development to clinical applications

Patented CRISPRclean™ technology is a foundational tool that improves the performance of next-generation sequencing and other molecular workflows by increasing sensitivity, reducing costs, and enabling novel discovery

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9

The new CRISPR-guided DNA base editing technologies are designed to efficiently induce "transversion" alterations of DNA bases while minimizing levels of unwanted "bystander" mutation